艾美珠单抗促进内皮细胞表面因子Xa生成
研究用两种细胞培养模型检验艾美珠单抗能否在内皮细胞表面促进因子X激活,发现内皮细胞支持艾美珠单抗介导的因子Xa生成且水平取决于因子IXa浓度,加入FEIBA后因子Xa生成呈剂量依赖性增加,内皮细胞活化后生成速率进一步增强;而因子VIII(a)存在时因子Xa生成有限、有明显滞后期且不依赖因子IXa浓度。
要点
- 内皮细胞可支持艾美珠单抗介导的因子IXa激活因子X。
- 加入FEIBA后内皮细胞表面因子Xa生成呈剂量依赖性增加。
- 内皮细胞活化可进一步增强因子Xa生成速率。
核心结论
- 艾美珠单抗促进内皮细胞表面因子Xa生成,加入FEIBA后生成显著增强,这为两者联用所见的血栓并发症提供了潜在机制。
研究设计与样本
- 研究采用两种细胞培养模型,检测艾美珠单抗在内皮细胞上促进因子X激活的能力。
主要发现
- 内皮细胞可支持艾美珠单抗介导的因子IXa激活因子X,因子Xa生成水平取决于可用因子IXa的浓度。
- 在两种模型中,向艾美珠单抗中加入FEIBA均使内皮细胞上因子Xa生成呈剂量依赖性增加。
- 内皮细胞活化可进一步增强因子Xa生成速率。
- 与艾美珠单抗不同,因子VIII(a)存在时因子Xa生成有限,伴有明显滞后期,且在这些条件下不依赖因子IXa浓度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mimics FVIIIa, has revolutionized the treatment of these patients. However, the use of an activated prothrombin complex concentrate [FEIBA (Takeda)] to treat breakthrough bleeding in patients on emicizumab has been associated with thrombotic complications including a unique microangiopathy. OBJECTIVES: We hypothesized that the thrombotic complications observed with the combination of emicizumab and FEIBA might be due to excessive expression of procoagulant activity on the surface of endothelial cells. METHODS: We examined the ability of emicizumab to promote FX activation on endothelial cells using 2 cell culture models. RESULTS: We found that endothelial cells readily support emicizumab-mediated activation of FX by FIXa. The level of FXa generation depends on the concentration of available FIXa. The addition of FEIBA to emicizumab increased FXa generation in a dose-dependent manner on endothelial cells in both models. The rate of FXa generation was further enhanced by endothelial cell activation. However, unlike emicizumab, we found limited FXa generation in the presence of FVIII(a), which followed a significant lag time and was not dependent on FIXa concentration under these conditions. CONCLUSION: Emicizumab promotes FXa generation on the surface of endothelial cells, which is markedly enhanced in the presence of FEIBA. These findings demonstrate a potential mechanism for the thrombotic complications seen with the combined use of emicizumab and FEIBA.
引用
- Fager AM, Ellsworth P, Key NS, et al. Emicizumab promotes factor Xa generation on endothelial cells. J Thromb Haemost. 2024. PMID: 38460838. doi:10.1016/j.jtha.2024.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。